These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11450158)

  • 1. [Hemorrhagic cystitis related to the high-dose conditioning therapy in a bone marrow recipient].
    Machaczka M; Rucińska M; Piatkowska-Jakubas B; Załuska A; Skotnicki AB
    Przegl Lek; 2001; 58(1):51-3. PubMed ID: 11450158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin E2 bladder instillation for the treatment of hemorrhagic cystitis after allogeneic bone marrow transplantation.
    Laszlo D; Bosi A; Guidi S; Saccardi R; Vannucchi AM; Lombardini L; Longo G; Fanci R; Azzi A; De Santis R
    Haematologica; 1995; 80(5):421-5. PubMed ID: 8566882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
    Copelan EA; Biggs JC; Szer J; Thompson JM; Crilley P; Brodsky I; Klein JL; Kapoor N; Harman GS; Avalos BR
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy.
    Thomas AE; Patterson J; Prentice HG; Brenner MK; Ganczakowski M; Hancock JF; Pattinson JK; Blacklock HA; Hopewell JP
    Bone Marrow Transplant; 1987 Apr; 1(4):347-55. PubMed ID: 3139113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivariate analysis of risk factors for hemorrhagic cystitis after hematopoietic stem cell transplantation.
    Tsuboi K; Kishi K; Ohmachi K; Yasuda Y; Shimizu T; Inoue H; Matsumoto M; Hattori K; Yoshiba F; Watanabe S; Ogawa Y; Kawada H; Yabe H; Yabe M; Kato S; Hotta T
    Bone Marrow Transplant; 2003 Nov; 32(9):903-7. PubMed ID: 14561991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial.
    Vose JM; Reed EC; Pippert GC; Anderson JR; Bierman PJ; Kessinger A; Spinolo J; Armitage JO
    J Clin Oncol; 1993 Jul; 11(7):1306-10. PubMed ID: 8315426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemorrhagic cystitis--a manifestation of graft versus host disease?
    Ost L; Lönnqvist B; Eriksson L; Ljungman P; Ringdén O
    Bone Marrow Transplant; 1987 Jun; 2(1):19-25. PubMed ID: 3139114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and cost of hyperhydration for the prevention of hemorrhagic cystitis in bone marrow transplant recipients.
    Ballen KK; Becker P; Levebvre K; Emmons R; Lee K; Levy W; Stewart FM; Quesenberry P; Lowry P
    Oncology; 1999 Nov; 57(4):287-92. PubMed ID: 10575313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the benefits of sodium 2-mercaptoethane sulfonate (MESNA) therapy for children undergoing high-dose chemotherapy].
    Sato J; Takaue Y; Saito S; Okamoto Y; Hirao A; Shimizu T; Abe T; Watanabe T; Kawano Y; Ninomiya T
    Rinsho Ketsueki; 1993 Jan; 34(1):7-12. PubMed ID: 8450612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemorrhagic cystitis associated with allogeneic and autologous bone marrow transplantation for malignant neoplasms in adults.
    Kohno A; Takeyama K; Narabayashi M; Tamayose K; Watanabe T; Adachi I; Tobisu K; Tobinai K; Shimoyama M
    Jpn J Clin Oncol; 1993 Feb; 23(1):46-52. PubMed ID: 8459641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hematuric cystitis after bone marrow allograft: a case].
    Bontemps I; Frappaz D; Levignes F; Freycon F
    Pediatrie; 1992; 47(7-8):525-9. PubMed ID: 1336164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemorrhagic cystitis after conditioning for bone marrow transplantation and its prophylaxis.
    Moriyama Y; Koike T; Shibata A
    Jpn J Clin Oncol; 1984 Dec; 14 Suppl 1():531-6. PubMed ID: 6441037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation.
    Shepherd JD; Pringle LE; Barnett MJ; Klingemann HG; Reece DE; Phillips GL
    J Clin Oncol; 1991 Nov; 9(11):2016-20. PubMed ID: 1941060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of hemorrhagic cystitis following allogeneic bone marrow transplant preparative regimens with cyclophosphamide and busulfan: role of continuous bladder irrigation.
    Turkeri LN; Lum LG; Uberti JP; Abella E; Momin F; Karanes C; Sensenbrenner LL; Haas GP
    J Urol; 1995 Mar; 153(3 Pt 1):637-40. PubMed ID: 7861502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.
    Lu C; Braine HG; Kaizer H; Saral R; Tutschka PJ; Santos GW
    Cancer Treat Rep; 1984 May; 68(5):711-7. PubMed ID: 6373004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan.
    Carpenter PA; Marshall GM; Giri N; Vowels MR; Russell SJ
    Bone Marrow Transplant; 1996 Sep; 18(3):489-94. PubMed ID: 8879607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support.
    Meisenberg B; Lassiter M; Hussein A; Ross M; Vredenburgh JJ; Peters WP
    Bone Marrow Transplant; 1994 Aug; 14(2):287-91. PubMed ID: 7994244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
    Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
    Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.